Merck's Keytruda extends recurrence-free survival in high-risk melanoma in late-stage study

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

The Phase 3 EORTC1325/KEYNOTE-054 study assessing Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) as monotherapy in patients with surgically resected high-risk melanoma met its primary endpoint of recurrence-free survival (RFS). The study will continue in order to evaluate other endpoints, including overall survival.

The results will be submitted for presentation at an upcoming medical conference and will be filed with regulatory authorities.